{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T07:10:22Z","timestamp":1738653022145,"version":"3.35.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-025-03690-9","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T06:33:12Z","timestamp":1738650792000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of camrelizumab combined with chemotherapy as second-line treatment for locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma"],"prefix":"10.1186","volume":"23","author":[{"given":"Yinfang","family":"Gu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofang","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junlin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guowu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"key":"3690_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71:209\u201349.","journal-title":"Cancer J Clin"},{"key":"3690_CR2","doi-asserted-by":"publisher","first-page":"S137","DOI":"10.1016\/j.jamcollsurg.2019.08.305","volume":"229","author":"JA Kincaid","year":"2019","unstructured":"Kincaid JA, Maine RG, Wren SM, et al. Sex disparities in access to surgical care in Malawi: a community-and hospital-based survey. J Am Coll Surg. 2019;229:S137\u20138.","journal-title":"J Am Coll Surg"},{"key":"3690_CR3","doi-asserted-by":"publisher","first-page":"e0231456","DOI":"10.1371\/journal.pone.0231456","volume":"15","author":"H-K Jung","year":"2020","unstructured":"Jung H-K, Tae CH, Lee H-A, et al. Treatment pattern and overall survival in esophageal cancer during a 13-year period: a nationwide cohort study of 6,354 Korean patients. PLoS ONE. 2020;15:e0231456.","journal-title":"PLoS ONE"},{"key":"3690_CR4","doi-asserted-by":"publisher","first-page":"974684","DOI":"10.3389\/fonc.2022.974684","volume":"12","author":"J Wang","year":"2022","unstructured":"Wang J, Zhang K, Liu T, et al. Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in locally advanced esophageal cancer: a meta-analysis. Front Oncol. 2022;12:974684.","journal-title":"Front Oncol"},{"key":"3690_CR5","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1093\/annonc\/mdh231","volume":"15","author":"K Muro","year":"2004","unstructured":"Muro K, Hamaguchi T, Ohtsu A, et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol. 2004;15:955\u20139.","journal-title":"Ann Oncol"},{"key":"3690_CR6","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1038\/sj.bjc.6603750","volume":"96","author":"E van Meerten","year":"2007","unstructured":"van Meerten E, Eskens F, Van Gameren E, et al. First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study. Br J Cancer. 2007;96:1348\u201352.","journal-title":"Br J Cancer"},{"key":"3690_CR7","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1245\/s10434-011-2049-9","volume":"19","author":"N Ando","year":"2012","unstructured":"Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68\u201374.","journal-title":"Ann Surg Oncol"},{"key":"3690_CR8","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","volume":"33","author":"MA Postow","year":"2015","unstructured":"Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33:1974\u201382.","journal-title":"J Clin Oncol"},{"key":"3690_CR9","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","volume":"398","author":"J-M Sun","year":"2021","unstructured":"Sun J-M, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398:759\u201371.","journal-title":"Lancet"},{"key":"3690_CR10","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1001\/jama.2021.12836","volume":"326","author":"H Luo","year":"2021","unstructured":"Luo H, Lu J, Bai Y, et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. JAMA. 2021;326:916\u201325.","journal-title":"JAMA"},{"key":"3690_CR11","doi-asserted-by":"crossref","unstructured":"Chau I, Doki Y, Ajani JA et al. Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): first results of the CheckMate 648 study. In. American Society of Clinical Oncology. 2021.","DOI":"10.1200\/JCO.2021.39.15_suppl.LBA4001"},{"key":"3690_CR12","doi-asserted-by":"publisher","first-page":"iv130","DOI":"10.1093\/annonc\/mdz154.011","volume":"30","author":"J Metges","year":"2019","unstructured":"Metges J, Francois E, Shah M, et al. The phase 3 KEYNOTE-181 study: pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer. Ann Oncol. 2019;30:iv130.","journal-title":"Ann Oncol"},{"key":"3690_CR13","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S1470-2045(20)30110-8","volume":"21","author":"J Huang","year":"2020","unstructured":"Huang J, Xu J, Chen Y, et al. Camrelizumab versus investigator\u2019s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2020;21:832\u201342.","journal-title":"Lancet Oncol"},{"key":"3690_CR14","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","volume":"20","author":"K Kato","year":"2019","unstructured":"Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:1506\u201317.","journal-title":"Lancet Oncol"},{"key":"3690_CR15","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1200\/JCO.21.01926","volume":"40","author":"L Shen","year":"2022","unstructured":"Shen L, Kato K, Kim S-B, et al. Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized phase III study. J Clin Oncol. 2022;40:3065\u201376.","journal-title":"J Clin Oncol"},{"key":"3690_CR16","doi-asserted-by":"publisher","first-page":"e16023","DOI":"10.1200\/JCO.2021.39.15_suppl.e16023","volume":"39","author":"Q Yao","year":"2021","unstructured":"Yao Q, Fu Z, Chen Q, et al. Real-world clinical effectiveness and safety of camrelizumab in esophageal squamous cell carcinoma. J Clin Oncol. 2021;39:e16023\u201316023.","journal-title":"J Clin Oncol"},{"key":"3690_CR17","doi-asserted-by":"crossref","unstructured":"Xu R-h, Luo H, Lu J et al. ESCORT-1st: a randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC). In. American Society of Clinical Oncology. 2021.","DOI":"10.1200\/JCO.2021.39.15_suppl.4000"},{"key":"3690_CR18","doi-asserted-by":"crossref","unstructured":"Xia J, Meng X, Ji Y et al. 482. Second-line of camrelizumab plus nimotuzumab in advanced esophageal squamous cell carcinoma (ESCC): a single-arm, open-label, phase 2 trial. Diseases of the Esophagus. 2023;36. Supplement_2:doad052-263.","DOI":"10.1093\/dote\/doad052.263"},{"key":"3690_CR19","doi-asserted-by":"publisher","first-page":"887011","DOI":"10.3389\/fonc.2022.887011","volume":"12","author":"F Li","year":"2022","unstructured":"Li F, Li H, Su X, et al. Trends in incidence and mortality of esophageal cancer in China 1990\u20132019: a joinpoint and age-period-cohort analysis. Front Oncol. 2022;12:887011.","journal-title":"Front Oncol"},{"key":"3690_CR20","doi-asserted-by":"publisher","first-page":"426","DOI":"10.21147\/j.issn.1000-9604.2019.03.04","volume":"31","author":"Y He","year":"2019","unstructured":"He Y, Li D, Shan B, et al. Incidence and mortality of esophagus cancer in China, 2008\u20132012. Chin J Cancer Res. 2019;31:426.","journal-title":"Chin J Cancer Res"},{"key":"3690_CR21","doi-asserted-by":"crossref","unstructured":"Li B, Liu Y, Peng J et al. Trends of esophageal cancer incidence and mortality and its influencing factors in China. Risk Manag Healthc Policy. 2021 Nov 30;14:4809\u20134821.","DOI":"10.2147\/RMHP.S312790"},{"key":"3690_CR22","doi-asserted-by":"crossref","unstructured":"Wang Z. Neoadjuvant camrelizumab combined with chemotherapy and apatinib for locally advanced thoracic esophageal squamous cell carcinoma (ESCC): a single-arm, open-label, phase ib study. In. American Society of Clinical Oncology. 2021.","DOI":"10.1200\/JCO.2021.39.15_suppl.4047"},{"key":"3690_CR23","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/s41467-022-28408-3","volume":"13","author":"J Xu","year":"2022","unstructured":"Xu J, Li Y, Fan Q, et al. Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2). Nat Commun. 2022;13:857.","journal-title":"Nat Commun"},{"key":"3690_CR24","doi-asserted-by":"crossref","unstructured":"Lu Z, Zhao J, Yang Z, et al. Effectiveness and safety of camrelizumab in advanced esophageal cancer: a prospective multicenter observational cohort studies (ESCORT-RWS). In. American Society of Clinical Oncology. 2023.","DOI":"10.1200\/JCO.2023.41.16_suppl.4049"},{"key":"3690_CR25","doi-asserted-by":"publisher","first-page":"100644","DOI":"10.1016\/j.drup.2019.100644","volume":"46","author":"A Leonetti","year":"2019","unstructured":"Leonetti A, Wever B, Mazzaschi G, et al. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer. Drug Resist Updates. 2019;46:100644.","journal-title":"Drug Resist Updates"},{"key":"3690_CR26","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1245\/s10434-013-2935-4","volume":"20","author":"M-F Chen","year":"2013","unstructured":"Chen M-F, Yang Y-H, Lai C-H, et al. Outcome of patients with esophageal cancer: a nationwide analysis. Ann Surg Oncol. 2013;20:3023\u201330.","journal-title":"Ann Surg Oncol"},{"key":"3690_CR27","doi-asserted-by":"publisher","first-page":"14736","DOI":"10.18632\/aging.103532","volume":"12","author":"M-j Qiu","year":"2020","unstructured":"Qiu M-j, Yang S-l, Wang M-m, et al. Prognostic evaluation of esophageal cancer patients with stages I-III. Aging. 2020;12:14736.","journal-title":"Aging"},{"key":"3690_CR28","doi-asserted-by":"publisher","first-page":"505","DOI":"10.4143\/crt.2020.1198","volume":"54","author":"JH Kim","year":"2022","unstructured":"Kim JH, Ahn B, Hong S-M, et al. Real-world efficacy data and predictive clinical parameters for treatment outcomes in advanced esophageal squamous cell carcinoma treated with immune checkpoint inhibitors. Cancer Res Treatment: Official J Korean Cancer Association. 2022;54:505\u201316.","journal-title":"Cancer Res Treatment: Official J Korean Cancer Association"},{"key":"3690_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-019-5446-2","volume":"19","author":"NM Meindl-Beinker","year":"2019","unstructured":"Meindl-Beinker NM, Betge J, Gutting T, et al. A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA). BMC Cancer. 2019;19:1\u20138.","journal-title":"BMC Cancer"},{"key":"3690_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13014-019-1377-y","volume":"14","author":"J Chen","year":"2019","unstructured":"Chen J, Yin W, Yao H, Gu W. Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma. Radiat Oncol. 2019;14:1\u20138.","journal-title":"Radiat Oncol"},{"key":"3690_CR31","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s10388-020-00778-x","volume":"18","author":"K Tanaka","year":"2021","unstructured":"Tanaka K, Yamasaki M, Makino T, et al. Analysis of prognostic factors in patients with lymph node recurrence after radical esophagectomy: importance of locoregional therapy. Esophagus. 2021;18:195\u2013202.","journal-title":"Esophagus"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03690-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-03690-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03690-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T06:33:19Z","timestamp":1738650799000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-025-03690-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3690"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-03690-9","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,4]]},"assertion":[{"value":"6 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. The experimental protocol was established and approved by the Medical Ethics Committee of the Meizhou People\u2019s Hospital (Huangtang Hospital) (the ethical approval number:2021-C-98).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}